565 related articles for article (PubMed ID: 32039024)
1. Reverting Immune Suppression to Enhance Cancer Immunotherapy.
Guerrouahen BS; Maccalli C; Cugno C; Rutella S; Akporiaye ET
Front Oncol; 2019; 9():1554. PubMed ID: 32039024
[TBL] [Abstract][Full Text] [Related]
2. The exploitation of enzyme-based cancer immunotherapy.
Chandan G; Saini AK; Kumari R; Chakrabarti S; Mittal A; Sharma AK; Saini RV
Hum Cell; 2023 Jan; 36(1):98-120. PubMed ID: 36334180
[TBL] [Abstract][Full Text] [Related]
3. Immune escape mechanisms and immunotherapy of urothelial bladder cancer.
Yang Z; Xu Y; Bi Y; Zhang N; Wang H; Xing T; Bai S; Shen Z; Naz F; Zhang Z; Yin L; Shi M; Wang L; Wang L; Wang S; Xu L; Su X; Wu S; Yu C
J Clin Transl Res; 2021 Aug; 7(4):485-500. PubMed ID: 34541363
[TBL] [Abstract][Full Text] [Related]
4. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
6. Overcoming tumor-mediated immunosuppression.
Schlößer HA; Theurich S; Shimabukuro-Vornhagen A; Holtick U; Stippel DL; von Bergwelt-Baildon M
Immunotherapy; 2014; 6(9):973-88. PubMed ID: 25341119
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive cells in tumor immune escape and metastasis.
Liu Y; Cao X
J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
[TBL] [Abstract][Full Text] [Related]
8. Targeting iNOS to increase efficacy of immunotherapies.
Ekmekcioglu S; Grimm EA; Roszik J
Hum Vaccin Immunother; 2017 May; 13(5):1105-1108. PubMed ID: 28121247
[TBL] [Abstract][Full Text] [Related]
9. Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Yong SB; Chung JY; Song Y; Kim J; Ra S; Kim YH
Biomaterials; 2019 Oct; 219():119401. PubMed ID: 31398571
[TBL] [Abstract][Full Text] [Related]
10. Improving cancer immunotherapy by targeting tumor-induced immune suppression.
Stewart TJ; Smyth MJ
Cancer Metastasis Rev; 2011 Mar; 30(1):125-40. PubMed ID: 21249424
[TBL] [Abstract][Full Text] [Related]
11. Targeting the immune system in cancer.
Chaudhuri D; Suriano R; Mittelman A; Tiwari RK
Curr Pharm Biotechnol; 2009 Feb; 10(2):166-84. PubMed ID: 19199949
[TBL] [Abstract][Full Text] [Related]
12. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
13. Immune Escape in Glioblastoma: Mechanisms of Action and Implications for Immune Checkpoint Inhibitors and CAR T-Cell Therapy.
Yu C; Hsieh K; Cherry DR; Nehlsen AD; Resende Salgado L; Lazarev S; Sindhu KK
Biology (Basel); 2023 Dec; 12(12):. PubMed ID: 38132354
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for colorectal cancer: where are we heading?
Basile D; Garattini SK; Bonotto M; Ongaro E; Casagrande M; Cattaneo M; Fanotto V; De Carlo E; Loupakis F; Urbano F; Negri FV; Pella N; Russano M; Brunetti O; Scartozzi M; Santini D; Silvestris N; Casadei Gardini A; Puzzoni M; Calvetti L; Cardarelli N; Aprile G
Expert Opin Biol Ther; 2017 Jun; 17(6):709-721. PubMed ID: 28375039
[TBL] [Abstract][Full Text] [Related]
15. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
[TBL] [Abstract][Full Text] [Related]
17. Boosting immune responses in lung tumor immune microenvironment: A comprehensive review of strategies and adjuvants.
Gao F; You X; Yang L; Zou X; Sui B
Int Rev Immunol; 2024 Mar; ():1-29. PubMed ID: 38525925
[TBL] [Abstract][Full Text] [Related]
18. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
19. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets.
Tie Y; Tang F; Wei YQ; Wei XW
J Hematol Oncol; 2022 May; 15(1):61. PubMed ID: 35585567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]